GeoVax Labs, a biotechnology company developing human vaccines, has expanded its partnership with United States-based Leidos, to develop malaria vaccine candidates, it was reported yesterday.
The work will be supported under an agreement granted to Leidos from the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP). USAID has tasked Leidos with advancing promising vaccine candidates against P. falciparum malaria and selected the GeoVax MVA-VLP platform as part of this development effort.
GeoVax's vaccine technology is based on its live Modified Vaccinia Ankara platform, which generates vaccine antigens, in the form of multimeric proteins or non-infectious VLPs, in the individual being vaccinated.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer